NCT06668753Not yet recruiting
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Effect of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors on Non-alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetic Patients with Diabetic Nephropathy
Source: ClinicalTrials.gov · Last updated 31 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease. And its role in improvement of Albuminuria and CKD progression.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 114 (estimated)
- First submitted
- 6 Sept 2024
- Start date
- 1 Nov 2024
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Assiut University
- NCT number
- NCT06668753
What you commit to
- Study type: Observational
- Planned participants: 114
- From 1 Nov 2024 to the primary completion date, 30 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Type 1 diabetes or non-diabetic patients 2. BMI ≥40 kg/m2 3. Other causes of chronic liver disease (e.g., Hepatitis B virus, Hepatitis c virus, HIV, autoimmune disease, Wilson disease, drugs, alpha one antitrypsin deficiency).
- 4\. Patients use of drugs known to cause hepatic steatosis (e.g., amiodarone, valproate, tamoxifen, methotrexate, corticosteroids, contraceptive pills) 5. Detection of biliary duct obstruction based on imaging studies. 6. Patient with history of liver transplantation 7. liver cirrhosis (on basis of ultrasonography and MRI) or hepatocellular carcinoma (evidence on triphasic CT or MRI).
- 8\. Intolerance or allergy SGLT2-I or any other substance in the tablets. 9. Refused to consent to this study.
Who the study is looking for
- \-
- Patients from 20 - 60 years old:
- Patients Diagnosed as type 2 diabetes since ≥6 months
- Patients Diagnosed with CKD GIII - IV non-HD
- Patients Diagnosed with Metabolic associated fatty liver disease
Age in the registry: 20 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.